Last updated: September 30, 2025
Sponsor: Clinigen K.K.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Epilepsy
Treatment
Midazolam
Clinical Study ID
NCT05313308
BUCCOLAM PMS
jRCT2031210712
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
Participants with non-convulsive status epilepticus
Participants treated with study drug outside the medical institution
Participants receiving an additional dose of study drug
Exclusion Criteria Participants have any contraindication to midazolam.
Study Design
Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Midazolam
Phase:
Study Start date:
June 01, 2021
Estimated Completion Date:
May 31, 2027
Connect with a study center
Takeda selected site
Tokyo,
JapanSite Not Available
Clinigen selected site
Tokyo 1850147,
JapanActive - Recruiting
Takeda selected site
Tokyo 1850147,
JapanActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.